Health Care & Hospital Law
Aug. 13, 2010
Regulators Push for 'Orphan' Drug Treatments
An employee of Novato-based BioMarin Pharmaceutical Inc. works on a purifying process for the drug Aldurazyme, which is used to treat a rare genetic disorder that affects one out of 100,000 people.
Daily Journal Staff Writer
There was a time when Americans suffering from so-called orphaned diseases truly were alone in the world. Before the Orphan Drug Act became law in 1983, the U.S. Food and Drug Administration approved almost no drugs for treatment of diseases that affect 200,000 or fewer Americans. Yet more than 6,800 orphan diseases afflict at least 25 million people.
Last year, the FDA's Office o...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In